{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:04:56Z","timestamp":1792087496286,"version":"4.4.0"},"reference-count":0,"publisher":"Instituto Nacional de Salud Publica","issue":"4","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Salud Publica Mex"],"abstract":"<jats:p>Objetivo. Estimar la prevalencia de ansiedad generalizada (GAD, por sus siglas en ingl\u00e9s) entre abril y junio de 2020. Material y m\u00e9todos. Dise\u00f1o transversal repetido basado en la Encovid-19, una serie de encuestas telef\u00f3nicas mensuales con muestras representativas de M\u00e9xico (N= 833-1 674). El cuestionario incluye la escala GAD-2 y en julio se a\u00f1adi\u00f3 la GAD-7; se examin\u00f3 su validez interna con an\u00e1lisis facto\u00adrial confirmatorio y su validez concurrente con variables sociodemogr\u00e1ficas. Con la GAD-7 como criterio, se calcul\u00f3 la validez predictiva de la GAD-2. Se estim\u00f3 la prevalencia mensual con la GAD-2. Resultados. La GAD-7 y la GAD- 2 son confiables y v\u00e1lidas. La GAD-2 tiene una sensibilidad de 0.87 y una especificidad de 0.90. La prevalencia mensual se mantuvo alta y estable, entre 30.7 y 32.6%. El GAD se concentr\u00f3 en mujeres, personas desocupadas y de bajo nivel socioecon\u00f3mico. Conclusiones. El GAD es un problema de salud p\u00fablica que se agrav\u00f3 con la pandemia por Covid-19.<\/jats:p>","DOI":"10.21149\/12257","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T15:38:52Z","timestamp":1625845132000},"page":"478-485","source":"Crossref","is-referenced-by-count":30,"title":["Prevalencia mensual de trastorno de ansiedad generalizada durante la pandemia por Covid-19 en M\u00e9xico"],"prefix":"10.21149","volume":"63","author":[{"given":"Pablo","family":"Gait\u00e1n-Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"P\u00e9rez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireya","family":"Vilar-Compte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Teruel-Belismelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8786","published-online":{"date-parts":[[2021,6,18]]},"container-title":["Salud P\u00fablica de M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/saludpublica.mx\/index.php\/spm\/article\/download\/12257\/12117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/saludpublica.mx\/index.php\/spm\/article\/download\/12257\/12117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T15:39:06Z","timestamp":1625845146000},"score":1,"resource":{"primary":{"URL":"https:\/\/saludpublica.mx\/index.php\/spm\/article\/view\/12257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,6,18]]}},"URL":"https:\/\/doi.org\/10.21149\/12257","relation":{},"ISSN":["1606-7916","0036-3634"],"issn-type":[{"value":"1606-7916","type":"electronic"},{"value":"0036-3634","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,18]]}}}